© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Dupilumab, Tezepelumab Gain Ground for Severe Asthma but Overall Biologic Adherence Rates Found Low: 2 Studies from 2025 AAAAI/WAO
February 12, 2025
AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.
AXS-05 Safety, Tolerability in Major Depressive Disorder Confirmed in Pooled Analysis of GEMINI and ASCEND Trials
February 12, 2025
Pooled data from the pivotal randomized clinical trials were consistent with prior outcomes supporting early occurrence and resolution of the most common TEAEs.
Transdermal Peanut Patch Shows Increased Clinical Benefit Over 5-Year Study
February 12, 2025
AAAAI 2025. Treatment response rates with daily use of the VIASKIN peanut patch increased from 39% at baseline to 73.3% at 60 months in youth aged 4 to 11 years.
Overlap in Pathophysiology Suggests New Approaches to Acute Pain May Transfer to Relief from Chronic Pain: A Closer Look
February 12, 2025
Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.
17 Adult Vaccines: Who to Consider for Each
February 11, 2025
A review of 4 factors can help primary care clinicians with an initial decision about adult vaccination: Health, Age, Lifestyle, and Occupation, or HALO.
As US Fentanyl Use Declines, Polysubstance Abuse Including Fentanyl Soars: Millennium Health Signals Report
February 11, 2025
Fentanyl overdoses increasingly reveal combined use of stimulants including cocaine and methamphetamine, according to the 2025 update.
Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-ILD Trial in Progressive Pulmonary Fibrosis
February 11, 2025
Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.
Suzetrigine (Journvax) Fits Neatly in a Multimodal Strategy to Manage Acute Pain, According to Edward Mariano, MD, MAS
February 11, 2025
Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.
Use of Perioperative Multimodal Pain Management in the US Remains Low, Expert Says
February 10, 2025
An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.
Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain
February 10, 2025
AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.